Therefore, we propose that the combinatorial activation of p53 and TLR5 pathways could affect tumor microenvironment, increase anti-tumor immunity by recruitment of immune cells to the tumor site and thereby improve cancer treatment. The gene discussed is TP53; the disease is cancer.